Ajanta Pharma Receives US FDA Form-483 With Five Observations At Pathan Facility

Ajanta Pharma Ltd, a leading Indian pharmaceutical manufacturer, has received a Form-483 from the US FDA following an inspection at its Pathan facility. The regulator noted five observations, indicating areas where the company’s practices did not fully meet required standards.

Regulatory Context

Form-483 is issued when FDA inspectors identify conditions that may violate the Food, Drug, and Cosmetic Act. While not an immediate enforcement action, it signals the need for corrective measures to ensure compliance with global quality standards.

Business Implications

Ajanta Pharma’s US operations contribute significantly to its revenue. Addressing the FDA’s concerns will be critical to maintaining supply continuity and safeguarding its reputation in regulated markets. The company is expected to respond with corrective and preventive action plans.

Key Highlights

• US FDA issues Form-483 with five observations
• Inspection conducted at Ajanta Pharma’s Pathan facility
• Observations highlight compliance gaps in manufacturing practices
• Company expected to submit corrective action plan
• US market remains vital for Ajanta Pharma’s growth strategy

Sources: Business Standard, Economic Times, US FDA Inspection Reports